Source: American Society of Clinical Oncology. Conference titles: Annual Meeting of the American Society of Clinical Oncology. Unidade: FM
Assunto: HEMATOLOGIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MASSUMOTO, C. M. et al. Busulfan plus melphalan (bu/mel) followed by interleukin-2 (il-2) as a preparative regimen for autologus bone marrow transplantation for acute myelogenous leukemia. American Society of Clinical Oncology. Los Angeles: Faculdade de Medicina, Universidade de São Paulo. . Acesso em: 17 out. 2024. , 1995APA
Massumoto, C. M., Ostronoff, M., Zambon, E., Almeida, M. C. de, Boehringer, B. L., Chamone, D. de A. F., & Dulley, F. L. (1995). Busulfan plus melphalan (bu/mel) followed by interleukin-2 (il-2) as a preparative regimen for autologus bone marrow transplantation for acute myelogenous leukemia. American Society of Clinical Oncology. Los Angeles: Faculdade de Medicina, Universidade de São Paulo.NLM
Massumoto CM, Ostronoff M, Zambon E, Almeida MC de, Boehringer BL, Chamone D de AF, Dulley FL. Busulfan plus melphalan (bu/mel) followed by interleukin-2 (il-2) as a preparative regimen for autologus bone marrow transplantation for acute myelogenous leukemia. American Society of Clinical Oncology. 1995 ; 14 340.[citado 2024 out. 17 ]Vancouver
Massumoto CM, Ostronoff M, Zambon E, Almeida MC de, Boehringer BL, Chamone D de AF, Dulley FL. Busulfan plus melphalan (bu/mel) followed by interleukin-2 (il-2) as a preparative regimen for autologus bone marrow transplantation for acute myelogenous leukemia. American Society of Clinical Oncology. 1995 ; 14 340.[citado 2024 out. 17 ]